{
    "clinical_study": {
        "@rank": "51998", 
        "arm_group": [
            {
                "arm_group_label": "drug (metformin and gliclazide)", 
                "description": "The first group (Group 1) consisted of patients that used metformin (1000 mg bid) and gliclazide (60 mg qd)."
            }, 
            {
                "arm_group_label": "drug (metformin, gliclazide and vildagliptin)", 
                "description": "The second group (Group 2) consisted of patients that used vildagliptin (50 mg bid) in addition to the same amount of metformin and gliclazide since their HbA1c were detected 7 % or over."
            }
        ], 
        "brief_summary": {
            "textblock": "This study investigated how vildagliptin (a di-peptidyl peptidase 4 inhibitor) affects\n      portal vein pressure and hepatosteatosis in patients with type 2 diabetes mellitus."
        }, 
        "brief_title": "Does Vildagliptin Affect Portal Vein Pressure In Patients With Type 2 Diabetes Mellitus? A Cross Sectional Study", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Drug Mechanism", 
            "Drug Usage"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "Group 1 used metformin (1000 mg bid) and gliclazide (60 mg qd); Group 2 used the same\n      amounts of metformin and gliclazide, with the addition of vildagliptin (50 mg bid). The\n      patients were prospectively assigned to each of these two groups for the purpose of this\n      study. Using Doppler ultrasound, all cases were measured for portal vein flow velocity,\n      portal vein flow and portal vein diameter. Degree of hepatosteatosis was also recorded."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        -type 2 DM cases and at least 3 months used the same drugs (metformin and gliclazide or\n        metformin and gliclazide and vildagliptin)\n\n        Exclusion Criteria:\n\n          -  used alcohol and cigarettes\n\n          -  chronic liver disease,\n\n          -  chronic renal failure,\n\n          -  active infection\n\n          -  patients using certain drugs which may affect portal pressure such as propronalol,\n\n          -  calcium channel blockers,\n\n          -  angiotensin-converting enzyme inhibitors,\n\n          -  angiotensin receptor blockers and isosorbit monohydrate"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "type 2 Diabetes Mellitus (DM)"
            }
        }, 
        "enrollment": {
            "#text": "97", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01963130", 
            "org_study_id": "ISRCTN73824458"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Vildagliptin", 
                "Gliclazide"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Vildagliptin", 
            "Portal Vein Pressure", 
            "Hepatosteatosis"
        ], 
        "lastchanged_date": "October 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Istanbul", 
                    "country": "Turkey", 
                    "zip": "34093"
                }, 
                "name": "Bezmialem VU"
            }
        }, 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_groups": "2", 
        "official_title": "Does Vildagliptin Affect Portal Vein Pressure In Patients With Type 2 Diabetes Mellitus? A Cross Sectional Study", 
        "overall_official": {
            "affiliation": "Bezmialem VU", 
            "last_name": "Cumali Karatoprak, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Turkey: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "This study investigated how vildagliptin (a di-peptidyl peptidase 4 inhibitor) affects portal vein pressure in patients with type 2 diabetes mellitus. Portal vein flow velocity, portal vein flow, and portal vein diameter of all cases were measured by Doppler ultrasound in both groups.", 
            "measure": "This study investigated the effect of the used type 2 DM drug, vildagliptin, a DPP-4 inhibitor, on portal hemodynamics.", 
            "safety_issue": "Yes", 
            "time_frame": "at least 3 month (mean 7.8 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01963130"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Bezmialem Vakif University", 
            "investigator_full_name": "Cumali Karatoprak", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Patients were examined in the left decubitus position with a Logiq 9 Review (GE, Milwaukee, WI, USA) ultrasound device and a 3.5-mHz convex transducer probe was used. Gray scale and color Doppler features were used. All segments of the liver were examined and the presence and degree of hepatosteatosis was recorded", 
            "measure": "This study investigated the effect of the used type 2 DM drug, vildagliptin, a DPP-4 inhibitor, on hepatosteatosis.", 
            "safety_issue": "Yes", 
            "time_frame": "followed for at least 3 months (mean 7.8 months)"
        }, 
        "source": "Bezmialem Vakif University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bezmialem Vakif University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}